The metabolic syndrome

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 65, Issue 240, 2005, Pages 3-13

  Boehm, Bernhard O ^a   Claudi Boehm, Simone ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Adipokinome; Adiponectin; ATP III criteria; Diabetes mellitus; Endothelial dysfunction; Metabolic syndrome; Microalbuminuria

Indexed keywords

PROINSULIN; INSULIN; LIPID;

CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; EPIDEMIC; FEMALE; GENE INTERACTION; HORMONAL REGULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; MALE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; ALBUMINURIA; ANIMAL; INFLAMMATION; PHYSIOLOGY; PREVALENCE; REVIEW; VASCULAR ENDOTHELIUM; CLINICAL FEATURE; HEREDITY; LIPID ANALYSIS; MICROANGIOPATHY; TREATMENT INDICATION;

ALBUMINURIA; ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; PREVALENCE;

EID: 23744431903     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510500236044     Document Type: Conference Paper

References (59)

1. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 2002; 51: 3069-76.
2. Wilson PWF. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin N Am 2004; 33: 467-481.
3. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104-9.
4. Yki-Järvinen H. Insulin resistance and endothelial dysfunction. Best Practice & Research Clin Endocrinol Metab 2003; 17: 411-430.
5. Reaven GM: Syndrome X. Blood Press 1992; 4s: 13-16.
6. Nestel P. Nutritional aspects in the causation and management of the metabolic syndrome. Endocrinol Metab Clin N Am 2004; 33: 483-492.
7. Stone NJ. Focus on lifestyle change and the metabolic syndrome. Endocrinol Metab Clin N Am 2004; 33: 493-508.
8. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967; 4: 36-41.
9. Haller H. Epidemiologie und assoziierte Risikofaktoren der Hyperlipoproteinamie [Epidemiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med 1977; 32: 124-128.
10. Singer P. Zur Diagnostik der primären Hyperlipoproteinämien [Diagnosis of primary hyperlipoproteinemias]. Z Gesamte Inn Med 1977; 32: 129-133.
11. Leonhardt W, Hanefeld M, Schneider H, Haller H. Importance of adipose tissue hypertrophy for the pathogenesis of maturity-onset diabetes. Z Gesamte Inn Med 1975; 30: 52-4.
12. Haller H, Leonhardt W, Moser W, Hanefeld M. Relation of blood pressure to the body weight index and to metabolic parameters. Z Gesamte Inn Med. 1973; 28s: 211-3.
13. Haller H, Leonhardt W, Hanefeld M, Julius U. Relationship between adipocyte hypertrophy and metabolic disturbances. Endokrinologie 1979; 74: 63-72.
14. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
15. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
16. Reaven GM. The Metabolic Syndrome: Requiescat in Pace. Clin Chem 2005, in press.
17. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 1997; 46: 1594-1600.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-553.
20. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; 1999. Available at: http://whqlibdoc.who.int/hq/1999/ WHO_NCD_NCS_99.2.pdf. Accessed December 12, 2003.
21. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-43.
22. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
23. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med 1998; 128: 524-533.
24. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999; 22: 659-660.
25. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Bio. Chem 1993; 268, 26055-26058.
26. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286, 327-334.
27. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AE. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
28. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50: 1511-25.
29. Boden G, Carnell LH. Nutritional effects of fat on carbohydrate metabolism. Best Practice & Research Clin Endocrinol Metab 2003; 17: 399-410.
30. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32s, 14-23.
31. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004; 109: 1349-53.
32. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003; 89: 601-9.
33. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kB. Nature Med 2005; 11: 193-90.
34. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Sturmvoll M, Weyer C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51: 1889-95.
35. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, Zinman B, Haffner SM; insulin atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004; 53: 2623-32.
36. Akahoshi M, Amasaki Y, Soda M, Tominaga T, Ichimaru S, Nakashima E, Seto S, Yano K. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res. 2001; 24: 337-43.
37. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, LIM KR, Lee HC, Huh KB, Cha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004; 164: 2169-75.
38. Rowley K, O'Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr Diab Rep. 2003; 3: 80-6.
39. Mano T, Masuyama T, Yamamoto K, Naito J, Kondo H, Nagano R, Tanuochi J, Hori M, Inoue M, Kamada T. Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound Am Heart J 1996; 131: 231-238.
40. Tooke JE. Microvascular function in human diabetes: a physiologic perspective Diabetes 1995; 44: 721-726.
41. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective Endocrine Rev 2001; 22: 36-52.
42. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 1992; 340: 1111-1115.
43. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347-55.
44. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, Kuzuya H, Shimatsu A, Ogawa Y. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care. 2004; 27: 2488-90.
45. Li WG, Gavrila D, Liu X, Gunnlaugsson S, Stoll LL, McCormick MI, Sigmund CD, Tang C, Weintraub NL. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004; 109: 2221-6.
46. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003; 3: 293-8.
47. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003; 144: 2195-200.
48. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1139-1142.
49. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
50. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-1257.
51. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3221.
52. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Organow RG, Thomsen T, Tunstall-Pedeo H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
53. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
54. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
55. Zimmet P, Shaw J, Alberti KG. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003; 20: 693-702.
56. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; i: 785-789.
57. Xydakis AM, Ballantyne CM. Management of metabolic syndrome: statins. Endocrinol Metab Clin N Am 2004; 33: 509-523.
58. Shields TM, Hennekens CH. Management of metabolic syndrome: aspirin. Endocrinol Metab Clin N Am 2004; 33: 577-593.
59. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin N Am 2004; 33: 595-616.